The 18 references in paper статья Редакционная (2017) “НИЗКОМОЛЕКУЛЯРНЫЕ ГЕПАРИНЫ: ОРИГИНАЛЬНЫЕ ПРЕПАРАТЫ И ИХ БИОАНАЛОГИ - ВЫБОР В КЛИНИЧЕСКОЙ ПРАКТИКЕ. СЕМИНАР” / spz:neicon:aterotromboz:y:2017:i:2:p:142-151

1
Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. ThrombHaemost, 2007, 98: 756-64.
(check this in PDF content)
2
Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest1998, 114: 489S–510S.
(check this in PDF content)
3
Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 126: 188S–203S.
(check this in PDF content)
4
Ohman EM, Granger CG, Rice L, et al. Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. TheComplicationAfter Thrombocytopenia Caused by Heparin (CATCH) Registry Steering Committee. J Thromb Thrombolysis,2005, 19: 11–9.
(check this in PDF content)
5
Oliveira GB, Anstrom KJ, Honeycutt EF, et al. Intravenous unfrac-tionated heparin, patient profile, and the magnitude of thrombocy-topenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH Registry (abstr). Eur Heart J,2005, 725.
(check this in PDF content)
6
Hochman JS, Wali AU, Barvila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J,1999, 138: 313–8.
(check this in PDF content)
7
Ellis V, Scully MF, Kakkar VV. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem. J, 1986, 238: 329-333.
(check this in PDF content)
8
Holmer E, Kurachi K, Soderstrom G. The molecularweight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor Xia, Factor XIIa and kallikrein by antithrombin. Biochem. J, 1981, 193: 395-400.
(check this in PDF content)
9
Fareed J, et al. Clin Pharmacokinet, 2003, 42(12):
(check this in PDF content)
10
3-1057. 10. Mascellani G, GuerriniM, Torri G, et al. Characterization of di- and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydro-β-D-glucosamine or 1,6-anhydro-β-D-mannosamine residues. Carbohydrate research, 2007, 342: 835-842.
(check this in PDF content)
11
Adiguzel C, Walter PJ, Hoppensteadt D, et al. Structural and functional characterization of low molecular weight heparins: impact on the developments of guidelines for generic products. Clinical and Applied Thrombosis/Hemostasis, 2009, 15(2): 137-144.
(check this in PDF content)
12
European Pharmacopoeia 5.3 01/2006: 1097.
(check this in PDF content)
13
Adiguzel C, Jeske WP, Hoppensteadt D, et al. Структурные и функциональные характеристики низкомолекулярных гепаринов в свете разработки руководств по применению генерических продуктов. Clinical and Applied Trombosis/Hemostasis, 2009 April, 15: 2.
(check this in PDF content)
14
Jeske W, Walenga J, Hoppensteadt D et al. Differentiating low-molecular- weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin. Thromb. Hemost., 2008, 34: 74-85.
(check this in PDF content)
15
Adiguzel C, Jeske W, Hoppensteadt D et al. Structural and functional characterization of low-molecularweight heparins: impact on the development of guidelines for generic products. Clin. Appl. Thromb. Hemost., 2009, 15: 137-144.
(check this in PDF content)
16
European Medicines Agency (EMEA). Committee for medicinal products for human use (CHMP). Cuigelines on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight-heparins. (EMEA/CHMP/BMWP/118264/2007). http: //www.emea.europa.eu.
(check this in PDF content)
17
Harenberg J, Kakkar A, Bergqvist D et al, on behalf of the subcommittee on control of anticoagulation of the SSC of the ISTH. Recommendations on biosimilar low-molecular-weight heparins. J. Thromb. Haemost., 2009, 7: 1222-1225.
(check this in PDF content)
18
Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the Nation’s Biosimilars Program. N Engl J Med, 2011, 365: 385-388.
(check this in PDF content)